Search research articles
Contact Us
Filters
Showing results (11-20 of 38) with videos related to
Page
of 4
Sort By:
British Journal of Clinical Pharmacology
|
March 24, 2011
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans
Aili L Lazaar, Lisa E Sweeney, Alexander J MacDonald, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 9, 2013
Predictors of objective cough frequency in chronic obstructive pulmonary disease
Helen Sumner, Ashley Woodcock, Umme Kolsum, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
November 25, 2003
Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent
Altaf S Kazi, Shidan Lotfi, Elena A Goncharova, et al.
British Journal of Clinical Pharmacology
|
June 8, 2012
Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling
Jackie C Bloomer, Mike Nash, Alison Webb, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 22, 2012
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis
Richard B Moss, Sunil J Mistry, Michael W Konstan, et al.
Clinical Pharmacology in Drug Development
|
May 7, 2019
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants
Takayuki Iida, Yuki Matsuzawa, Hirofumi Ogura, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
February 18, 2003
IFN-gamma inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway
Yassine Amrani, Omar Tliba, Divaker Choubey, et al.
Respiratory Research
|
June 14, 2020
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
Aili L Lazaar, Bruce E Miller, Alison C Donald, et al.
The European Respiratory Journal
|
August 25, 2018
Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD
Aili L Lazaar, Bruce E Miller, Maggie Tabberer, et al.
Clinical Pharmacology in Drug Development
|
September 20, 2018
Pharmacokinetics, Excretion, and Mass Balance of [<sup>14</sup> C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
Claire Ambery, Graeme Young, Teresa Fuller, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 38) with videos related to
Sort By:
Page
of 4
British Journal of Clinical Pharmacology
|
March 24, 2011
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans
Aili L Lazaar, Lisa E Sweeney, Alexander J MacDonald, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 9, 2013
Predictors of objective cough frequency in chronic obstructive pulmonary disease
Helen Sumner, Ashley Woodcock, Umme Kolsum, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
November 25, 2003
Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent
Altaf S Kazi, Shidan Lotfi, Elena A Goncharova, et al.
British Journal of Clinical Pharmacology
|
June 8, 2012
Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling
Jackie C Bloomer, Mike Nash, Alison Webb, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 22, 2012
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis
Richard B Moss, Sunil J Mistry, Michael W Konstan, et al.
Clinical Pharmacology in Drug Development
|
May 7, 2019
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants
Takayuki Iida, Yuki Matsuzawa, Hirofumi Ogura, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
February 18, 2003
IFN-gamma inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway
Yassine Amrani, Omar Tliba, Divaker Choubey, et al.
Respiratory Research
|
June 14, 2020
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
Aili L Lazaar, Bruce E Miller, Alison C Donald, et al.
The European Respiratory Journal
|
August 25, 2018
Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD
Aili L Lazaar, Bruce E Miller, Maggie Tabberer, et al.
Clinical Pharmacology in Drug Development
|
September 20, 2018
Pharmacokinetics, Excretion, and Mass Balance of [<sup>14</sup> C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
Claire Ambery, Graeme Young, Teresa Fuller, et al.
Page
of 4